

References

- Abbas, SS, Awadallah, FM, Ibrahim, NA, Said, EG and Kamel, G, Design and synthesis of some 3-substituted-2-[(2,4-dichlorophenoxy)-methyl]quinazolin-4(3H)-one derivatives as potential anticonvulsant agents, *Chem. Pharm. Bull.*, 61, 679–687, 2013.
- Acharya, C, Coop, A, Polli, JE and Mackerell, AD, Recent advances in ligand-based drug design: relevance and utility of the conformationally sampled pharmacophore approach, *Curr. Comput. Aided Drug Des.*, 7, 10–22, 2011.
- Ahmed, SN and Siddiqi, ZA, Antiepileptic drugs and liver disease, *Seizure*, 15, 156–164, 2006.
- Al-Obaid, AM, Abdel-Hamide, SG, El-Kashef, HA, Abdel-Aziz, AA, El-Azab, AS, Al-Khamees, HA and El-Subbagh, HI, Substituted quinazolines, part 3. Synthesis, *in vitro* antitumor activity and molecular modelling study of certain 2-thieno-4(3H)-quinazolinone analogs, *Eur. J. Med. Chem.*, 44, 2379–2391, 2009.
- Ambrósio, AF, Soares-Da-Silva, P, Carvalho, CM and Carvalho, AP, Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024, *Neurochem. Res.*, 27, 121–130, 2002.
- Amir, M, Ali, I and Hassan, MZ, Design and synthesis of some new quinazolin-4-(3H)-ones as anticonvulsant and antidepressant agents, *Arch. Pharm. Res.*, 36, 61–68, 2013.
- Barañano, KW and Hartman, AL, The ketogenic diet: uses in epilepsy and other neurologic illnesses, *Curr. Treat. Options Neurol.*, 10, 410–419, 2008.
- Berg, AT, Berkovic, SF, Brodie, MJ, Buchhalter, J, Cross, JH, van Emde Boas, W, Engel, J, French, J, Glauser, TA, Mathern, GW, Moshe, SL, Nordli, D, Plouin, P and Scheffer, IE, Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009, *Epilepsia*, 51, 676–685, 2010.
- Bialer, M, Johannessen, SI, Kupferberg, HJ, Levy, RH, Perucca, E and Tomson, T, Progress report on new antiepileptic drugs: a summary of the Eighth Eilat conference (EILAT VIII), *Epilepsy Res.*, 73, 1–52, 2007.
- Björnsson, E, Hepatotoxicity associated with antiepileptic drugs, *Acta. Neurol. Scand.*, 118, 281–290, 2008.

- Boggan, WO, Meyer, JS, Steinberg, RM and Worthington, C, The effects of methaqualone on the seizure susceptibility of mice, *Psychopharmacology (Berl)*, 54, 45–49, 1977.
- Bromfield, EB, Cavazos, JE and Sirven, JI, Basic mechanisms underlying seizures and epilepsy, In: *An introduction to epilepsy [Internet]*. West Hartford (CT): American Epilepsy Society (US), 2006a.
- Bromfield, EB, Cavazos, JE and Sirven, JI, Neuropharmacology of antiepileptic drugs, In: *An introduction to epilepsy [Internet]*. West Hartford (CT): American Epilepsy Society (US), 2006b.
- Brown, D and Superti-Furga, G, Rediscovering the sweet spot in drug discovery, *Drug Discov. Today.*, 8, 1067–1077, 2003.
- Cain, SM and Snutch, TP, Voltage-gated calcium channels and disease, *Biofactors*, 37, 197–205, 2011.
- Castel-Branco, MM, Alves, GL, Figueiredo, IV, Falcão, AC and Caramona, MM, The maximal electroshock seizure (MES) model in the preclinical assessment of potential new antiepileptic drugs, *Methods Find. Exp. Clin. Pharmacol.*, 31, 101–106, 2009.
- Catarzi, D, Colotta, V and Varano, F, Competitive AMPA receptor antagonists, *Med. Res. Rev.*, 27, 239–278, 2007.
- Catarzi, D, Colotta, V, Varano, F, Cecchi, L, Filacchioni, G, Galli, A, Costagli, C and Carlà, V, 7-Chloro-4,5-dihydro-8-(1,2,4-triazol-4-yl)-4-oxo-1,2,4-triazolo[1,5-*a*]quinoxaline-2-carboxylates as novel highly selective AMPA receptor antagonists, *J. Med. Chem.*, 43, 3824–3826, 2000.
- Cavasotto, CN and Phatak, SS, Homology modeling in drug discovery: current trends and applications, *Drug Discov. Today.*, 14, 676–683, 2009.
- Chapman, AG, Glutamate and epilepsy, *J. Nutr.*, 130, 1043S–1045S, 2000.
- Chen, Z, Li, HL, Zhang, QJ, Bao, XG, Yu, KQ, Luo, XM, Zhu, WL and Jiang, HL, Pharmacophore-based virtual screening versus docking-based virtual screening: a benchmark comparison against eight targets, *Acta. Pharmacol. Sin.*, 30, 1694–1708, 2009.
- Chenard, BL, Menniti, FS, Pagnozzi, MJ, Shenk, KD, Ewing, FE and Welch, WM, Methaqualone derivatives are potent noncompetitive AMPA receptor antagonists, *Bioorg. Med. Chem. Lett.*, 10, 1203–1205, 2000.
- Chenard, BL, Welch, WM, Blake, JF, Butler, TW, Reinhold, A, Ewing, FE, Menniti, FS and Pagnozzi, MJ, Quinazolin-4-one alpha-amino-3-hydroxy-5-methyl-4-

- isoxazolepropionic acid (AMPA) receptor antagonists: structure–activity relationship of the C–2 side chain tether, *J. Med. Chem.*, 44, 1710–1717, 2001.
- Chimirri, A, De Sarro, G, Quartarone, S, Barreca, ML, Caruso, R, De Luca, L and Gitto, R, Search for noncompetitive 2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid receptor (AMPA) antagonists: synthesis, pharmacological properties, and computational studies, *Pure Appl. Chem.*, 76, 931–939, 2004.
- Chimirri, A, Gitto, R and Zappala, M, AMPA receptor antagonists, *Exp. Opin. Ther. Patents*, 9, 557–570, 1999.
- Culshaw, AJ, Bevan, S, Christiansen, M, Copp, P, Davis, A, Davis, C, Dyson, A, Dziadulewicz, EK, Edwards, L, Eggelte, H, Fox, A, Gentry, C, Groarke, A, Hallett, A, Hart, TW, Hughes, GA, Knights, S, Kotsonis, P, Lee, W, Lyothier, I, McBryde, A, McIntyre, P, Paloumbis, G, Panesar, M, Patel, S, Seiler, MP, Yaqoob, M and Zimmermann, K, Identification and biological characterization of 6-aryl-7-isopropylquinazolinones as novel TRPV1 antagonists that are effective in models of chronic pain, *J. Med. Chem.*, 49, 471–474, 2006.
- Czapiński, P, Blaszczyk, B and Czuczwar, SJ, Mechanisms of action of antiepileptic drugs, *Curr. Top. Med. Chem.*, 5, 3–14, 2005.
- Czuczwar, SJ and Patsalos, PN, The new generation of GABA enhancers. Potential in the treatment of epilepsy, *CNS Drugs*, 15, 339–350, 2001.
- Das, N, Dhanawat, M and Shrivastava, SK, An overview on antiepileptic drugs, *Drug Discov. Ther.*, 6, 178–193, 2012.
- Das, N, Dhanawat, M, Kulshrestha, A and Shrivastava, SK, Pharmacophoric modeling and atom-based 3D-QSAR of novel 1-aryl-3-(1-acylpiperidin-4-yl) urea as human soluble epoxide hydrolase inhibitors (sEHIs), *Med. Chem.*, 7, 581–592, 2011.
- de Boer, HM, Mula, M and Sander, JW, The global burden and stigma of epilepsy, *Epilepsy Behav.*, 12, 540–546, 2008.
- De Luca, L, Macchiarulo, A, Costantino, G, Barreca, ML, Gitto, R, Chimirri, A and Pellicciari, R, Binding modes of noncompetitive AMPA antagonists: a computational approach, *Farmacologia*, 2003, 58, 107–113.
- De Sarro, G, Ferreri, G, Gareri, P, Russo, E, De Sarro, A, Gitto, R and Chimirri, A, Comparative anticonvulsant activity of some 2,3-benzodiazepine derivatives in rodents, *Pharmacol. Biochem. Behav.*, 74, 595–602, 2003.

- De Sarro, G, Gitto, R, Russo, E, Ibbadu, GF, Barreca, ML, De Luca, L and Chimirri, A, AMPA receptor antagonists as potential anticonvulsant drugs, *Curr. Top. Med. Chem.*, 5, 31–42, 2005.
- Dingledine, R, Glutamatergic mechanisms related to epilepsy: ionotropic receptors. In: Noebels, JL, Avoli, M, Rogawski, MA, Olsen, RW, Delgado–Escueta and AV, Jasper's basic mechanisms of the epilepsies [Internet], 4th edition, Bethesda (MD): National Center for Biotechnology Information (US), 2012.
- Donevan, SD and Rogawski, MA, GYKI 52466, a 2,3–benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses, *Neuron*, 10, 51–59, 1993.
- Durrant, JD and McCammon, JA, Molecular dynamics simulations and drug discovery, *BMC Biol.*, 9, 71, 2011.
- El–Azab, AS, Abdel–Hamide, SG, Sayed–Ahmed, MM, Hassan, GS, El–Hadiyah, TM, Al–Shabanah, OA, Al–Deeb, OA and El–Subbagh, HI, Novel 4(3*H*)–quinazolinone analogs: synthesis and anticonvulsant activity, *Med. Chem. Res.*, 22, 2815–2827, 2013.
- El–Helby, AG and Wahab, MH, Design and synthesis of some new derivatives of 3*H*–quinazolin–4–one with promising anticonvulsant activity, *Acta Pharm.*, 53, 127–138, 2003.
- Engelborghs, S, D'Hooge, R and De Deyn, PP, Pathophysiology of epilepsy, *Acta Neurol. Belg.*, 100, 201–213, 2000.
- Englot, DJ, Chang, EF and Auguste, KI, Vagus nerve stimulation for epilepsy: a meta-analysis of efficacy and predictors of response, *J. Neurosurg.*, 115, 1248–1255, 2011.
- Eskandariyan, Z, Zadeh, ME, Tehrani, KHME, Mashayekhi, V and Kobarfard, F, Synthesis of thioether derivatives of quinazolin–4–one–2–thione and evaluation of their antiplatelet aggregation activity, *Arch. Pharm. Res.*, 37, 332–339, 2014.
- Ferreri, G, Chimirri A, Russo, E, Gitto, R, Gareri, P, De Sarro, A and De Sarro, G, Comparative anticonvulsant activity of *N*–acetyl–1–aryl–6,7–dimethoxy–1,2,3,4–tetrahydroisoquinoline derivatives in rodents, *Pharmacol. Biochem. Behav.*, 77, 85–94, 2004.
- Fiest, KM, Sajobi, TT and Wiebe, S, Epilepsy surgery and meaningful improvements in quality of life: results from a randomized controlled trial, *Epilepsia*, 55, 886–892, 2014.
- Figueiredo, TH, Qashu, F, Apland, JP, Aroniadou–Anderjaska, V, Souza, AP and Braga, MF, The GluK1 (GluR5) kainate/{alpha}–amino–3–hydroxy–5–methyl–4–

- isoxazolepropionic acid receptor antagonist LY293558 reduces soman-induced seizures and neuropathology, *J. Pharmacol. Exp. Ther.*, 336, 303–312, 2011.
- Fisher, RS, Acevedo, C, Arzimanoglou, A, Bogacz, A, Cross, JH, Elger, CE, Engel, J Jr, Forsgren, L, French, JA, Glynn, M, Hesdorffer, DC, Lee, BI, Mathern, GW, Moshé, SL, Perucca, E, Scheffer, IE, Tomson, T, Watanabe, M and Wiebe, S, ILAE official report: a practical clinical definition of epilepsy, *Epilepsia*, 55, 475–482, 2014.
- Georgey, H, Abdel-Gawad, N and Abbas, S, Synthesis and anticonvulsant activity of some quinazolin-4-(3*H*)-one derivatives, *Molecules*, 13, 2557–2569, 2008.
- Giannini, G, Battistuzzi, G, Vesci, L, Milazzo, FM, De Paolis, F, Barbarino, M, Guglielmi, MB, Carollo, V, Gallo, G, Artali, R and Dallavalle, S, Novel PARP-1 inhibitors based on a 2-propanoyl-3*H*-quinazolin-4-one scaffold, *Bioorg. Med. Chem. Lett.*, 24, 462–466, 2014.
- Gitto, R, Barreca, ML, De Luca, L, De Sarro, G, Ferreri, G, Quartarone, S, Russo, E, Constanti, A and Chimirri, A. Discovery of a novel and highly potent noncompetitive AMPA receptor antagonist, *J. Med. Chem.*, 46, 197–200, 2003.
- Goldenberg, MM, Overview of drugs used for epilepsy and seizures, *PT.*, 35, 392–415, 2010.
- Gomora, JC, Daud, AN, Weiergräber, M and Perez-Reyes, E, Block of cloned human T-type calcium channels by succinimide antiepileptic drugs, *Mol. Pharmacol.*, 60, 1121–1132, 2001.
- Granata, T, Cross, H, Theodore, W and Avanzini, G, Immune-mediated epilepsies, *Epilepsia*, 52, 5–11, 2011.
- Grasso, S, De Sarro, G, De Sarro, A, Micale, N, Zappalà, M, Puja, G, Baraldi, M and De Micheli, C, Synthesis and anticonvulsant activity of novel and potent 6,7-methylenedioxyphthalazin-1(2*H*)-ones, *J. Med. Chem.*, 43, 2851–2859, 2000.
- Greger, IH, Ziff, EB and Penn, AC, Molecular determinants of AMPA receptor subunit assembly, *Trends Neurosci.*, 30, 407–416, 2007.
- Gryder, DS and Rogawski, MA, Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons, *J. Neurosci.*, 23, 7069–7074, 2003.
- Gunthorpe, MJ, Large, CH and Sankar, R, The mechanism of action of retigabine (ezogabine), a first-in-class K⁺ channel opener for the treatment of epilepsy, *Epilepsia*, 53, 412–424, 2012.

- Halgren, T, New method for fast and accurate binding-site identification and analysis, *Chem. Biol. Drug Des.*, 69, 146–148, 2007.
- Harris, JA and Murphy, JA, Retigabine (ezogabine) as add-on therapy for partial-onset seizures: an update for clinicians, *Ther. Adv. Chronic Dis.*, 2, 371–376, 2011.
- Hibi, S, Ueno, K, Nagato, S, Kawano, K, Ito, K, Norimine, Y, Takenaka, O, Hanada, T and Yonaga, M, Discovery of 2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl)benzotrile (perampanel): a novel, noncompetitive α -amino-3-hydroxy-5-methyl-4-isoxazolepropanoic acid (AMPA) receptor antagonist, *J. Med. Chem.*, 55, 10584–10600, 2012.
- Hoffmann, T and Metternich, R, The future of medicinal chemistry, *Angew. Chem. Int. Ed.*, 51, 8670–8671, 2012.
- Howes, JF and Bell, C, Talampanel, *Neurotherapeutics*, 4, 126–129, 2007.
- Hu, Z, Zhou, X, Chen, J, Tang, C, Xiao, Z, Ying, D, Liu, Z and Liang, S, The venom of the spider *Selenocosmia jiafu* contains various neurotoxins acting on voltage-gated ion channels in rat dorsal root ganglion neurons, *Toxins (Basel)*, 6, 988–1001, 2014.
- Hughes, JP, Rees, S, Kalindjian, SB and Philpott, KL, Principles of early drug discovery, *Br. J. Pharmacol.*, 162, 1239–1249, 2011.
- Ismail, MA, Barker, S, Abou el-Ella, DA, Abouzeid, KA, Toubar, RA and Todd, MH, Design and synthesis of new tetrazolyl- and carboxy-biphenylmethyl-quinazolin-4-one derivatives as angiotensin II AT1 receptor antagonists, *J. Med. Chem.*, 49, 1526–1535, 2006.
- Jallon, P and Latour, P, Epidemiology of idiopathic generalized epilepsies, *Epilepsia*, 46, 10–14, 2005.
- Jayalakshmi, S, Panigrahi, M, Nanda, SK and Vadapalli, R, Surgery for childhood epilepsy, *Ann. Indian Acad. Neurol.*, 17, S69–S79, 2014.
- Jensen, AA, Christesen, T, Bolcho, U, Greenwood, JR, Postorino, G, Vogensen, SB, Johansen, TN, Egebjerg, J, Brauner-Osborne H and Clausen, RP, Functional characterization of Tet-AMPA [tetrazolyl-2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid] analogues at ionotropic glutamate receptors GluR1–GluR4. The molecular basis for the functional selectivity profile of 2-Bn-Tet-AMPA, *J. Med. Chem.*, 50, 4177–4185, 2007.
- Johannessen, CU, Mechanisms of action of valproate: a commentary, *Neurochem. Int.*, 37, 103–110, 2000.

- Joshua, SP and Mahapatra, AK, Epilepsy in tropics: Indian perspective, *J. Neurosci. Rural Pract.*, 4, 171–175, 2013.
- Kaul, PN, Drug discovery: past, present and future, *Prog. Drug. Res.*, 50, 9–105, 1998.
- Kew, JN and Kemp, JA, Ionotropic and metabotropic glutamate receptor structure and pharmacology, *Psychopharmacology (Berl)*, 179, 4–29, 2005.
- Kim do, Y and Rho, JM, The ketogenic diet and epilepsy, *Curr. Opin. Clin. Nutr. Metab. Care.*, 11, 113–120, 2008.
- Ko, J, Murga, LF, Wei, Y and Ondrechen, MJ, Prediction of active sites for protein structures from computed chemical properties, *Bioinformatics*, 21, i258–i265, 2005.
- Köhling, R, Voltage-gated sodium channels in epilepsy, *Epilepsia*, 43, 1278–1295, 2002.
- Kostov, H, Larsson, PG and Røste, GK, Is vagus nerve stimulation a treatment option for patients with drug-resistant idiopathic generalized epilepsy?, *Acta. Neurol. Scand. Suppl.*, 187, 55–58, 2007.
- Krahl, SE and Clark, KB, Vagus nerve stimulation for epilepsy: A review of central mechanisms, *Surg. Neurol. Int.*, 3, S255–S259, 2012.
- Krauss, GL, Perucca, E, Ben-Menachem, E, Kwan, P, Shih, JJ, Clément, JF, Wang, X, Bagul, M, Gee, M, Zhu, J and Squillacote, D, Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: Results from phase III extension study 307, *Epilepsia*, 55, 1058–1068, 2014.
- Kumar, A and Rajput, CS, Synthesis and anti-inflammatory activity of newer quinazolin-4-one derivatives, *Eur. J. Med. Chem.*, 44, 83–90, 2009.
- Kumar, KS, Ganguly, S, Veerasamy, R and De Clercq, E, Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazolin-4(3H)-ones, *Eur. J. Med. Chem.*, 45, 5474–5479, 2010.
- Kumar, P, Shrivastava, B, Pandeya, SN and Stables, JP, Design, synthesis and potential 6 Hz psychomotor seizure test activity of some novel 2-(substituted)-3- $\{[\text{substituted}]\text{amino}\}$ quinazolin-4(3H)-one, *Eur. J. Med. Chem.*, 46, 1006–1018, 2011.
- Kumar, S, Kaur, H and Kumar, A, Synthesis of new azetidinyll/thiazolidinonyl quinazolinone derivatives as antiparkinsonian agents, *Arabian J. Chem.*, 5, 475–484, 2012.
- Landmark, CJ, Targets for antiepileptic drugs in the synapse, *Med. Sci. Monit.*, 13, RA1–RA7, 2007.

- Lees, GJ, Pharmacology of AMPA/kainate receptor ligands and their therapeutic potential in neurological and psychiatric disorders, *Drugs*, 59, 33–78, 2000.
- Leivers, AL, Tallant, M, Shotwell, JB, Dickerson, S, Leivers, MR, McDonald, OB, Gobel, J, Creech, KL, Strum, SL, Mathis, A, Rogers, S, Moore, CB and Botyanszki, J, Discovery of selective small molecule type III phosphatidylinositol 4-kinase alpha (PI4KIII α) inhibitors as anti hepatitis C (HCV) agents, *J. Med. Chem.*, 57, 2091–2106, 2014.
- Leppik, IE, Zonisamide: chemistry, mechanism of action, and pharmacokinetics, *Seizure*, 13, S5–S9, 2004.
- Lerche, H, Jurkat–Rott, K and Lehmann–Horn, F, Ion channels and epilepsy, *Am. J. Med. Genet.*, 106, 146–159, 2001.
- Levy, RG, Cooper, PN and Giri, P, Ketogenic diet and other dietary treatments for epilepsy, *Cochrane Database Syst. Rev.*, 3, CD001903, 2012.
- Lima, LM and Barreiro, EJ, Bioisosterism: a useful strategy for molecular modification and drug design, *Curr. Med. Chem.*, 12, 23–49, 2005.
- Lindskog, S, Structure and mechanism of carbonic anhydrase, *Pharmacol. Ther.*, 74, 1–20, 1997.
- Lipinski, CA, Lead- and drug-like compounds: the rule-of-five revolution, *Drug Discov. Today Technol.*, 1, 337–341, 2004.
- Lounnas, V, Ritschel, T, Kelder, J, McGuire, R, Bywater, RP and Foloppe, N, Current progress in structure-based rational drug design marks a new mindset in drug discovery, *Comput. Struct. Biotechnol. J.*, 5, e201302011, 2013.
- Lowenstein, DH, Epilepsy after head injury: an overview, *Epilepsia*, 50, 4–9, 2009.
- Luszczki, JJ, Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions, *Pharmacol. Rep.*, 61, 197–216, 2009.
- Lynch, BA, Lambeng, N, Nocka, K, Kensel–Hammes, P, Bajjalieh, SM, Matagne, A and Fuks, B, The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam, *Proc. Natl. Acad. Sci. USA.*, 101, 9861–9866, 2004.
- MacCoss, M and Baillie, TA, Organic chemistry in drug discovery, *Science*, 303, 1810–1813, 2004.
- Malik, S and Khan, SA, Design and evaluation of new hybrid pharmacophore quinazolino-tetrazoles as anticonvulsant strategy, *Med. Chem. Res.*, 23, 207–223, 2014.

- Malik, S, Bahare, RS and Khan, SA, Design, synthesis and anticonvulsant evaluation of *N*-(benzo[*d*]thiazol-2-ylcarbamoyl)-2-methyl-4-oxoquinazoline-3(4*H*)-carbothioamide derivatives: a hybrid pharmacophore approach, *Eur. J. Med. Chem.*, 67, 1–13, 2013.
- Mandal, S, Moudgil, M and Mandal, SK, Rational drug design. *Eur. J. Pharmacol.*, 625, 90–100, 2009.
- Meldrum, BS and Rogawski, MA, Molecular targets for antiepileptic drug development, *Neurotherapeutics*, 4, 18–61, 2007.
- Menniti, FS, Chenard, BL, Collins, MB, Ducat, MF, Elliott, ML, Ewing, FE, Huang, JI, Kelly, KA, Lazzaro, JT, Pagnozzi, MJ, Weeks, JL, Welch, WM and White, WF, Characterization of the binding site for a novel class of noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonists, *Mol. Pharmacol.*, 58, 1310–1317, 2000.
- Moon, JB and Howe, WJ, Computer design of bioactive molecules: a method for receptor-based de novo ligand design, *Proteins*, 11, 314–328, 1991.
- Morgan, S, Grootendorst, P, Lexchin, J, Cunningham, C and Greyson, D, The cost of drug development: a systematic review, *Health Policy*, 100, 4–17, 2011.
- Niswender, CM and Conn, PJ, Metabotropic glutamate receptors: physiology, pharmacology, and disease, *Annu. Rev. Pharmacol. Toxicol.*, 50, 295–322, 2010.
- Pajouhesh, H and Lenz, GR, Medicinal chemical properties of successful central nervous system drugs, *NeuroRx*, 2, 541–553, 2005.
- Pal, D, Carpio, A and Sander, J, Neurocysticercosis and epilepsy in developing countries, *J. Neurol. Neurosurg. Psychiatry*, 68, 137–143, 2000.
- Palmada, M and Centelles, JJ, Excitatory amino acid neurotransmission. Pathways for metabolism, storage and reuptake of glutamate in brain, *Front. Biosci.*, 3, d701–d718, 1998.
- Patani, GA and LaVoie, EJ, Bioisosterism: a rational approach in drug design, *Chem. Rev.*, 96, 3147–3176, 1996.
- Perucca, E and Meador, KJ, Adverse effects of antiepileptic drugs, *Acta Neurol. Scand. Suppl.*, 181, 30–35, 2005.
- Perucca, E, Yasothan, U, Clincke, G and Kirkpatrick, P, Lacosamide, *Nat. Rev. Drug Discov.*, 7, 973–974, 2008.
- Perucca, P and Gilliam, FG, Adverse effects of antiepileptic drugs, *Lancet Neurol.*, 11, 792–802, 2012.

- Pitkänen, A, SV2A: more than just a new target for AEDs, *Epilepsy Curr.*, 5, 14–16, 2005.
- Rajshekhar, V, Raghava, MV, Prabhakaran, V, Oommen, A and Muliylil, J, Active epilepsy as an index of burden of neurocysticercosis in Vellore district, India, *Neurology*, 67, 2135–2139, 2006.
- Riss, J, Cloyd, J, Gates, J and Collins, S, Benzodiazepines in epilepsy: pharmacology and pharmacokinetics, *Acta. Neurol. Scand.*, 118, 69–86, 2008.
- Robinson, S, Systemic prenatal insults disrupt telencephalon development: implications for potential interventions, *Epilepsy Behav.*, 7, 345–363, 2005.
- Rogawski, M, Brivaracetam: a rational drug discovery success story, *Br. J. Pharmacol.*, 154, 1555–1557, 2008.
- Rogawski, MA and Hanada, T, Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist, *Acta Neurol. Scand. Suppl.*, 197, 19–24, 2013.
- Rogawski, MA, AMPA Receptors as an antiepileptic drug target, *Epilepsy. Curr.*, 11, 56–63, 2011.
- Rogovik, AL and Goldman, RD, Ketogenic diet for treatment of epilepsy, *Can. Fam. Physician*, 56, 540–542, 2010.
- Russo, E, Gitto, R, Citraro, R, Chimirri, A and De Sarro, G, New AMPA antagonists in epilepsy, *Expert Opin. Investig. Drugs*, 21, 1371–1389, 2012.
- Satlin, A, Kramer, LD and Laurenza, A, Development of perampanel in epilepsy, *Acta. Neurol. Scand.*, 127, 3–8, 2013.
- Schielke, GP, Kupina, NC, Boxer, PA, Bigge, CF, Welty, DF and Iadecola, C, The neuroprotective effect of the novel AMPA receptor antagonist PD152247 (PNQX) in temporary focal ischemia in the rat, *Stroke*, 30, 1472–1477, 1999.
- Schulze-Bonhage, A and Zentner, J, The preoperative evaluation and surgical treatment of epilepsy, *Dtsch. Arztebl. Int.*, 111, 313–319, 2014.
- Shariat, M, Samsudin, MW and Zakaria, Z, One-pot synthesis of 2-substituted 4*H*-3,1-benzoxazin-4-one derivatives under mild conditions using iminium cation from cyanuric chloride/dimethylformamide as a cyclizing agent, *Chem. Cent. J.*, 7, 58, 2013.
- Shi, LP, Jiang, KM, Jiang, JJ, Jin, Y, Tao, YH, Li, K, Wang, XH and Lin, J, Synthesis and antimicrobial activity of polyhalobenzonitrile quinazolin-4(3*H*)-one derivatives, *Bioorg. Med. Chem. Lett.*, 23, 5958–5963, 2013.

- Shih, JJ, Tatum, WO and Rudzinski, LA, New drug classes for the treatment of partial onset epilepsy: focus on perampanel, *Ther. Clin. Risk. Manag.*, 9, 285–293, 2013.
- Sil, A, Das, K, Das, NK, Chakraborty, D, Mazumdar, G and Tripathi, SK, Use of anti-epileptic drugs in a tertiary care hospital of Eastern India with emphasis on epilepsy due to neurocysticercosis, *Indian J. Pharmacol.*, 44, 106–110, 2012.
- Sills, GJ, The mechanisms of action of gabapentin and pregabalin, *Curr. Opin. Pharmacol.*, 6, 108–113, 2006.
- Stafstrom, CE, Other antiepileptic drugs. In: Wheless, JW, Willmore, LK and Brumback, RA, *Advanced therapy in epilepsy*, Shelton, CT: People's Medical Publishing House, 361–369, 2009.
- Steinhoff, BJ, Introduction: perampanel–new mode of action and new option for patients with epilepsy, *Epilepsia*, 55, 1–2, 2014.
- Suter, W, Hartmann, A, Poetter, F, Sagelsdorff, P, Hoffmann, P and Martus, HJ, Genotoxicity assessment of the antiepileptic drug AMP397, an Ames–positive aromatic nitro compound, *Mutat. Res.*, 518, 181–194, 2002.
- Szabados, T, Gigler, G, Gacsályi, I, Gyertyán, I and Lévy, G, Comparison of anticonvulsive and acute neuroprotective activity of three 2,3–benzodiazepine compounds, GYKI 52466, GYKI 53405, and GYKI 53655, *Brain Res. Bull.*, 55, 387–391, 2001.
- Tokura, Y, Ogai, M, Yagi, H, and Takigawa, M, Afloqualone photosensitivity: immunogenicity of afloqualone–photomodified epidermal cells, *Photochem. Photobiol.*, 60, 262–267, 1994.
- Tong, V, Teng, XW, Chang, TKH and Abbott, FS, Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats, *Toxicol. Sci.*, 86, 427–435, 2005.
- Traynelis, SF, Wollmuth, LP, McBain, CJ, Menniti, FS, Vance, KM, Ogden, KK, Hansen, KB, Yuan, H, Myers, SJ and Dingledine, R, Glutamate receptor ion channels: structure, regulation, and function, *Pharmacol. Rev.*, 62, 405–496, 2010.
- Treiman, DM, GABAergic mechanisms in epilepsy, *Epilepsia*, 42, 8–12, 2001.
- Turski, L, Huth, A, Sheardown, M, McDonald, F, Neuhaus, R, Schneider, HH, Dirnagl, U, Wiegand, F, Jacobsen, P and Ottow, E, ZK200775: a phosphonate quinoxalinedione AMPA antagonist for neuroprotection in stroke and trauma, *Proc. Natl. Acad. Sci. USA*, 95, 10960–10965, 1998.

- Ugale, VG and Bari, SB, Quinazolines: new horizons in anticonvulsant therapy, *Eur. J. Med. Chem.*, 80, 447–501, 2014.
- Ukrainets, IV, Taran, SG, Gorokhova, OV, Bezuglyi, PA and Turov, AV, 2–Carbethoxymethyl–4*H*–3,1–benzoxazin–4–one. 4. Reaction with anilines, *Chem. Het. Comp.*, 30, 204–207, 1994.
- Vezzani, A, Balosso, S and Ravizza, T, The role of cytokines in the pathophysiology of epilepsy, *Brain Behav. Immun.*, 22, 797–803, 2008.
- Vogel, HG, Rotarod method, In: *Drug discovery and evaluation: pharmacological assays*, 2nd edition, Springer, New York, 398, 2002.
- Vogl, C, Mochida, S, Wolff, C, Whalley, BJ and Stephens, GJ, The synaptic vesicle glycoprotein 2A ligand levetiracetam inhibits presynaptic Ca²⁺ channels through an intracellular pathway, *Mol. Pharmacol.*, 82, 199–208, 2012.
- Wang, HJ, Wei, CX, Deng, XQ, Li, FL and Quan, ZS, Synthesis and evaluation on anticonvulsant and antidepressant activities of 5–alkoxy–tetrazolo[1,5–*a*]quinazolines, *Arch. Pharm. (Weinheim)*, 342, 671–675, 2009.
- Weaver, DF, Principles and practice of computer–aided drug design as applied to the discovery of antiepileptic agents, In: Soltesz, I and Staley, K, *Computational neuroscience in epilepsy*, San Diego CA, Academic Press, 515–527, 2011.
- Welch, WM, Ewing, FE, Huang, J, Menniti, FS, Pagnozzi, MJ, Kelly, K, Seymour, PA, Guanowsky, V, Guhan, S, Guinn, MR, Critchett, D, Lazzaro, J, Ganong, AH, DeVries, KM, Staigers, TL and Chenard, BL, Atropisomeric quinazolin–4–one derivatives are potent noncompetitive alpha–amino–3–hydroxy–5–methyl–4–isoxazolepropionic acid (AMPA) receptor antagonists, *Bioorg. Med. Chem. Lett*, 11, 177–181, 2001.
- Wermuth, CG, Similarity in drugs: reflections on analogue design, *Drug Discov. Today*, 11, 348–354, 2006.
- White, HS, Smith MD and Wilcox KS, Mechanisms of action of antiepileptic drugs, *Int. Rev. Neurobiol.*, 81, 85–110, 2007.
- Willmore, LJ, Abelson, MB, Ben–Menachem, E, Pellock, JM and Shields, WD, Vigabatrin: 2008 update, *Epilepsia*, 50, 163–173, 2009.
- Wolfe, JF, Rathman, TL, Sleevi, MC, Campbell, JA and Greenwood, TD, Synthesis and anticonvulsant activity of some new 2–substituted 3–aryl–4(3*H*)–quinazolinones, *J. Med. Chem.*, 33, 161–166, 1990.
- Wulff, H, Castle, NA and Pardo, LA, Voltage–gated potassium channels as therapeutic drug targets, *Nat. Rev. Drug. Discov.*, 8, 982–1001, 2009.

- Yaari, Y, Selzer, ME and Pincus, JH, Phenytoin: mechanisms of its anticonvulsant action, *Ann. Neurol.*, 20, 171–184, 1986.
- Yamaguchi, S, Donevan, SD and Rogawski, MA, Anticonvulsant activity of AMPA/kainate antagonists: comparison of GYKI 52466 and NBOB in maximal electroshock and chemoconvulsant seizure models, *Epilepsy Res.*, 15, 179–184, 1993.
- Yamashita, H, Ohno, K, Amada, Y, Hattori, H, Ozawa–Funatsu, Y, Toya, T, Inami, H, Shishikura, J, Sakamoto, S, Okada, M and Yamaguchi, T, Effects of 2–[N–(4–chlorophenyl)–N–methylamino]–4H–pyrido[3.2–e]–1,3–thiazin–4–one (YM928), an orally active alpha–amino–3–hydroxy–5–methyl–4–isoxazolepropionic acid receptor antagonist, in models of generalized epileptic seizure in mice and rats, *J. Pharmacol. Exp. Ther.*, 308, 127–133, 2004.
- Yao, G, Zong, Y, Gu, S, Zhou, J, Xu, H, Mathews, II and Jin, R, Crystal structure of the glutamate receptor GLUA1 N–terminal domain, *Biochem. J.*, 438, 255–263, 2011.
- Yu, CW, Chang, PT, Hsin, LW and Chern, JW, Quinazolin–4–one derivatives as selective histone deacetylase–6 inhibitors for the treatment of Alzheimer's disease, *J. Med. Chem.*, 56, 6775–6791, 2013.
- Yu, FH and Catterall, WA, Overview of the voltage–gated sodium channel family, *Genome Biol.*, 4, 207, 2003.
- Zamponi, GW, Lory, P and Perez–Reyes, E, Role of voltage–gated calcium channels in epilepsy, *Pflugers Arch.*, 460, 395–403, 2010.
- Zappala, M, Grasso, S, Micale, N, Zuccalà, G, Menniti, FS, Ferreri, G, De Sarro, G and De Micheli, C, 1–aryl–6,7–methylenedioxy–3H–quinazolin–4–ones as anticonvulsant agents, *Bioorg. Med. Chem. Lett.*, 13, 4427–4430, 2003.
- Zawilska, JB, Wojcieszak, J and Olejniczak, AB, Prodrugs: a challenge for the drug development, *Pharmacol. Rep.*, 65, 1–14, 2013.
- Zheng, C, Yang, K, Liu, Q, Wang, MY, Shen, J, Vallés, AS, Lukas, RJ, Barrantes, FJ and Wu, J, The anticonvulsive drug lamotrigine blocks neuronal $\alpha 4\beta 2$ nicotinic acetylcholine receptors, *J. Pharmacol. Exp. Ther.*, 335, 401–408, 2010.

List of publications from Ph.D. research work

1. **Nirupam Das**, Meenakshi Dhanawat, Sushant Kumar Shrivastava. An overview on antiepileptic drugs. *Drug Discoveries and Therapeutics*. 2012, 6, 178–193.
2. **Nirupam Das**, Debapriya Garabadu, Anupam G. Banerjee, Sairam Krishnamurthy, Sushant Kumar Shrivastava. Synthesis and pharmacological evaluation of some *N*³-aryl/heteroaryl substituted 2-(2-chlorostyryl)-6,7-dimethoxy-quinazolin-4(3*H*)-ones as potential anticonvulsant agents. *Medicinal Chemistry Research*. 2014, 23, 4167–4176.
3. Nirupam Das, Anupam G. Banerjee, Sushant Kumar Shrivastava. Design, synthesis and pharmacological evaluation of *N*³ aryl/heteroaryl substituted 2-((benzyloxy and phenylthio) methyl) 6,7-dimethoxyquinazolin-4(3*H*)-ones as potential anticonvulsant agents. *Medicinal Chemistry*. 2014, 10, 800–809.

List of publications other than Ph.D. research work

1. Meenakshi Dhanawat, **Nirupam Das**, Ramesh C. Nagarwal, Sushant Kumar Shrivastava. Antimalarial drug development: past to present scenario. *Mini Review in Medicinal Chemistry*. 2009, 9, 1447–1469.
2. **Nirupam Das**, Meenakshi Dhanawat, Biswajit Dash, Ramesh C. Nagarwal, Sushant Kumar Shrivastava. Codrug: an efficient approach for drug optimization. *European Journal of Pharmaceutical Sciences*. 2010, 41, 571–588.
3. Abhilasha Verma, **Nirupam Das**, Meenakshi Dhanawat, Sushant Kumar Shrivastava. Conjugation of some NSAIDs with 5-phenyl-2-aminothiazole for reduced ulcerogenicity. *Thai Journal of Pharmaceutical Sciences*. 2010, 34, 49–57.
4. **Nirupam Das**, Meenakshi Dhanawat, Akanksha Kulshrestha, Sushant K. Shrivastava. Pharmacophoric modeling and atom-based 3D-QSAR of novel 1-aryl-3-(1-acylpiperidin-4-yl) urea as human soluble Epoxide Hydrolase inhibitors (sEHIs). *Medicinal Chemistry*. 2011, 7, 581–592.
5. Meenakshi Dhanawat, **Nirupam Das**, Sushant Kumar Shrivastava. Design, synthesis, anticonvulsant screening and 5HT_{1A/2A} receptor affinity of *N* (3) substituted 2,4 imidazolidinediones and oxazolidinediones. *Drug Discoveries and Therapeutics*. 2011, 5, 227–237.
6. **Nirupam Das**, Meenakshi Dhanawat, Biswajit Dash, Sushant. K. Shrivastava. Benzoxazinones as human peroxisome proliferator activated receptor gamma (PPAR γ) agonist: a docking studies using Glide. *Indian Journal of Pharmaceutical Sciences*. 2011, 73, 159–164.
7. **Nirupam Das**, Biswajit Dash, Meenakshi Dhanawat, Sushant Kumar Shrivastava. Design, synthesis, preliminary pharmacological evaluation and docking studies of some pyrazoline derivatives. *Chemical Papers*. 2012, 66, 67–74.

8. Akanksha Kulshrestha, Meenakshi Dhanawat, **Nirupam Das**, Sushant Kumar Shrivastava. Small molecules antileishmanials: a review. *Letters in Drug Design and Discovery*. 2012, 9, 535–548.
9. Shubhanjali Shukla, Pankaj Kumar, **Nirupam Das**, N.S.H.N. Moorthy, Sushant Kumar Shrivastava, Piyush Trivedi, Radhey Shyam Srivastava. Synthesis, characterization, biological evaluation and docking of coumarin coupled thiazolidinedione derivatives and its bioisosters as PPAR γ agonists. *Medicinal chemistry*. 2012, 8, 834–845.
10. Akanksha kulshrestha, **Nirupam Das**, Anupam G. Banerjee, Sushant Kumar Shrivastava. Design, synthesis and pharmacological evaluation of some pyrazolopyrimidin-6(7H)-one and tricyclic 8-oxo-dihydrooxazolopyrazolopyrimidin-9-ium chloride derivatives. *Arabian Journal of Chemistry*. 2014. DOI: 10.1016/j.arabjc.2014.03.012.

List of presentations

1. **Nirupam Das**, Meenakshi Dhanawat, Anupam Banerjee, Sushant K Shrivastava. Design, synthesis, pharmacological evaluation of quinazolin-4(3H)-one derivatives as anticonvulsant agents. 14th Asian Chemical congress at Bangkok, Thailand, 5–8th September, 2011 (Poster presentation).
2. **Nirupam Das**, Anupam G. Banerjee and Sushant Kumar Shrivastava. Active site prediction at AMPA (α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor site, docking studies and *in silico* pharmacokinetic studies of some quinazolin-4(3H)-ones. National Seminar on *Advances in Biotechnology Research. Current trends and future prospects* at Assam University Silchar, Silchar, India, 25–26th March, 2014 (Oral presentation).